检索结果-南通市图书馆

Is the measurement of drain amylase content useful for predicting pancreas-related complications after gastrectomy with systematic lymphadenectomy?

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2020年第14期26卷 1594-1600页

作者： Koki Nakanishi Mitsuro Kanda junichi sakamoto Yasuhiro Kodera Department of Gastroenterological Surgery(Surgery Ⅱ) Nagoya University Graduate School of MedicineNagoya 466-8550Japan Tokai Central Hospital Kakamigahara 504-8601Japan

Many studies investigating postoperative pancreatic fistula(POPF)after gastrectomy,including studies measuring drain amylase content(D-AMY)as a predictive factor have been *** article reviews previous studies and looks to the future of measuring D-AMY in patients after *** causes of pancreatic fluid leakage are;the parenchymal and/or thermal injury to the pancreas,and blunt injury to the pancreas by compression and *** of D-AMY to predict POPF has become common in clinical practice after pancreatic surgery and was later extended to the gastric *** studies have reported associations between D-AMY and POPF after gastrectomy,and the high value of D-AMY on postoperative day(POD)1 was an independent risk *** improve both sensitivity and specificity,attempts have been made to enhance the predictive accuracy of factors on POD 1 as well as on POD 3 as combined *** several studies have shown a high predictive ability of POPF,it has not necessarily been exploited in clinical *** problems remain unresolved;ideal timing for measurement,optimal cut-off value,and means of intervention after *** clinical trial could be imperative in order to develop D-AMY measurement in common clinical practice for gastric surgery.

关键词： Gastric cancer Drain amylase Postoperative pancreatic fistula Pancreasrelated complications Gastrectomy Early prediction

Knowledge,attitudes and practices towards avian influenza A(H5N1) among Cambodian women:A cross-sectional study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Asian Pacific Journal of Tropical Medicine 2012年第9期5卷 727-734页

作者： Mav Khun Chantha Heng Md.Harun-Or-Rashid Hideki Kasuya junichi sakamoto Young Leaders' Program in Healthcare Administration Nagoya University Graduate School of MedicineNagoyaJapan Communicable Disease Control Rapid Response TeamKampot Provincial Health DepartmentKampot ProvinceCambodia Department of Surgery Ⅱ Nagoya University Graduate School of MedicineNagoyaJapan

Objective:To measure highly pathogenic avian influenza(HPAI)-related knowledge,attitudes, and practices(KAPs) among Cambodian ***:This cross-sectional study selected 246 married women aged between 18-55 years who had backyard poultry and lived at least one year in the areas of the survey through multi-stage cluster *** average score of correct answers was generated to evaluate respondents’ knowledge(Good/Poor).attitudes(Positive/ Negative),and practices(Good/Bad).Results:We reported that about half of the respondents had good knowledge and good practices and four-fifth of them had positive attitudes towards *** ratios(ORs) and 95%confidence intervals(CIs) were estimated through a logistic regression model to explore contributing factors that raise their KAP *** of the sources were significant in increasing knowledge of the respondent,like television(OR=l.6.95%CI=1.0- 2.7),radio(OR=2.5.95%CI=l.3-4.9).leaflets/booklets(OR=2.1,95%CI=1.2-3.9),school students (OR=18.4.95%CI=2.4-142.9).village health volunteers(OR=4.5.95%CI=2.2-10.9) *** such as television(OR=3.7.95%CI=2.1-6.4).leaflets/booklets(OR=2.6,95%CI7=1.4-5.1).and public health staff(OR=2.2,95%CI=1.2-4.1) had similar influence on ***,we found similar effect on raising the attitudes of the responded,it was not ***: We report a satisfactory level of positive attitudes,and moderate level of knowledge and practices related to HPAI among Cambodian *** KAPs through television,radio and other medias may be more efficient than using usual information,education and communication materials to prevent HPAI.

关键词： Highly pathogenic avian influenza Knowledge Attitudes Practices Kampot Cambodia

Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2006年第9期12卷 1412-1415页

作者： Michiya Kobayashi junichi sakamoto Tsutomu Namikawa Ken Okamoto Takehiro Okabayashi Kengo Ichikawa Keijiro Araki Department of Tumor Surgery Kochi Medical School KohasuOko-choNankoku 783-8505Japan Department of Epidemiological & Clinical Research Information Management Kyoto University Graduate School of Medicine Yoshida Hon-machiSakyo-ku 606-8317Japan Department of Tumor Surgery Kochi Medical School Kohasu Oko-cho Nankoku 783-8505 Japan

AIM： To examine the paclitaxel concentrations in plasma and ascites after its intravenous administration in patients with ascites due to peritonitis carcinomatosa resulting from advanced gastric cancer. METHODS： Two patients with ascites due to peritonitis carcinomatosa resulting from gastric cancer were included in this study. The paclitaxel concentrations in plasma and ascites were investigated for 72 h in case 1 and 168 h in case 2 after intravenous administration. RESULTS： The paclitaxel concentration in plasma peaked immediately after administration, followed by rapid decrease below the threshold value of 0.1 μmol （85 ng/mL） within 24 h. In contrast, the paclitaxel concentration in ascites increased gradually for 24 h after administration to a level consistent with the level found in plasma. After 24 h the level of paclitaxel in ascites and plasma became similar, with the optimal level being maintained up to 72 h following administration. CONCLUSION： The concentration of paclitaxel in ascites is maintained within the optimal level for the treatment of cancer cells for up to 72 h after intravenous administration. Paclitaxel is a promising drug for the treatment of malignant ascites of gastric cancer.

关键词： Paclitaxel Chemotherapy Gastric cancer Peritoneal carcinomatosis Pharmacokinetic study Ascites

Evaluation and treatment of malignant ascites secondary to gastric cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2015年第39期21卷 10936-10947页

作者： Hiromichi Maeda Michiya Kobayashi junichi sakamoto Cancer Treatment Center Kochi Medical School Tokai Central Hospital Sohara Higashijimacho

Malignant ascites affects approximately 10% of patients with gastric cancer(gC), and poses significant difficulties for both patients and clinicians. In addition to the dismal general condition of affected patients and the diversity of associated complications such as jaundice and ileus, problems in assessing scattered tumors have hampered the expansion of clinical trials for this condition. However, the accumulation of reported studies is starting to indicate that the weak response to treatment in g C patients with malignant ascites is more relevant to their poor prognosis rather than to the ascites volume at diagnosis. Therefore, precise assessment of initial state of ascites, repetitive evaluation of treatment efficacy, selection of suitable treatment, and swift transition to other treatment options as needed are paramount to maximizing patient benefit. Accurately determining ascites volume is the crucial first step in clinically treating a patient with malignant ascites. Ultrasonography is commonly used to identify the existence of ascites, and several methods have been proposed to estimate ascites volume. Reportedly, the sum of the depth of ascites at five points(named "five-point method") on three panels of computed tomography images is well correlated to the actual ascites volume and/or abdominal girth. This method is already suited to repetitive assessment due to its convenience compared to the conventional volume rendering method. Meanwhile, a new concept, "Clinical Benefit Response in g C(CBR-GC)", was recently introduced to measure the efficacy of chemotherapy for malignant ascites of g C. CBR-GC is a simple and reliable patient-oriented evaluation system based on changes in performance status and ascites, and is expected to become an important clinical endpoint in future clinical trials. The principal of treatment for g C patients with ascites is palliation and prevention of ascites-related symptoms. The treatment options are various, including a standar

关键词： Ascites Clinical benefit Gastric cancer Peritoneal

Impact of prior chemotherapy with two different fluoropyrimidines on the efficacy of capecitabine plus irinotecan or FOLFIRI with or without bevacizumab in metastatic colorectal cancer:a post hoc analysis of the AXEPT study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Communications 2023年第4期43卷 519-522页

作者： Satoru Iwasa Zi-Xian Wang Kei Muro Satoshi Morita Young Suk Park Dongsheng Zhang Yasuhide Yamada junichi sakamoto TaeWon Kim Department of Gastrointestinal Medical Oncology National Cancer Center HospitalTokyoJapan Department of Medical Oncology Sun Yat-sen University Cancer CenterGuangzhouGuangdongP.R.China Department of Clinical Oncology Aichi Cancer Center HospitalNagoyaJapan Department of Biomedical Statistics and Bioinformatics Graduate School of MedicineKyoto UniversityKyotoJapan Division of Hematology-Oncology Department of MedicineSamsung Medical CenterSungkyunkwan University School of MedicineSeoulKorea Comprehensive Cancer Center National Center for Global Health and MedicineTokyoJapan Department of Medical Oncology Hamamatsu University School of MedicineShizuokaJapan Tokai Central Hospital KakamigaharaJapan Department of Oncology Asan Medical CenterUniversity of UlsanCollege of MedicineSeoulKorea

Dear Editor,Recently,the phase III Asian XELIRI(capecitabine plus irinotecan)ProjecT(AXEPT)study demonstrated the non-inferiority of modified capecitabine plus irinotecan(mXELIRI)±bevacizumab(Bev)to fluorouracil plus leucovorin with irinotecan(FOLFIRI)±Bev in terms of overall survival(OS)as a second-line treatment for patients with metastatic colorectal cancer[1,2].In the past decade,oral prodrugs of fluorouracil-containing regimens have shown similar efficacies to intravenous fluorouracilcontaining regimens.

关键词： FOLFIRI colorectal metastatic

Study protocol of the Asian XELIRI ProjecT(AXEPT):a multinational,randomized,non-inferiority,phase Ⅲ trial of second-line chemotherapy for metastatic colorectal cancer, comparing the eicacy and safety of XELIRI with or without bevacizumab versus FOLFIRI w

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Journal of Cancer 2016年第12期35卷 735-742页

作者： Masahito Kotaka Ruihua Xu Kei Muro Young Suk Park Satoshi Morita Satoru Iwasa Hiroyuki Uetake Tomohiro Nishina Hiroaki Nozawa Hiroshi Matsumoto Kentaro Yamazaki Sae-Won Han Wei Wang Joong Bae Ahn Yanhong Deng Sang-Hee Cho Yi Ba Keun-Wook Lee Tao Zhang Taroh Satoh Marc E.Buyse Baek-Yeol Ryoo Lin Shen junichi sakamoto Tae Won Kim Gastrointestinal Cancer Center Sano HospitalHyogo 655-0031Japan. State Key Laboratory of Oncology in South China Department of Medical OncologyCollaborative Innovation Center for Cancer MedicineSun Yat-sen Univer-sity Cancer CenterGuangzhouGuangdong 510060P.R.China. Depart-ment of Clinical Oncology Aichi Cancer Center HospitalNagoya 464-8681Japan. Department of Medicine Samsung Medical CenterSungkyunkwan University School of MedicineSeoul 135-710South Korea. Department of Biomedical Statistics and Bioinformatics Graduate School of MedicineKyoto UniversityKyoto 606-8501Japan. Gastrointestinal Medical Oncology Division National Cancer Center HospitalTokyo 104-0045Japan. Depart-ment of Surgical Specialties Graduate SchoolTokyo Medical and Dental UniversityTokyo 113-8519Japan. Department of Gastrointestinal Medical Oncology National Hospital Organization Shikoku Cancer CenterMatsuy-ama 791-0280Japan. Department of Surgical Oncology The University of TokyoTokyo 113-0033Japan. Department of Surgery Tokyo Metropoli-tan Komagome HospitalTokyo 113-8677Japan. Division of Gastrointestinal Oncology Shizuoka Cancer CenterShizuoka 411-8777Japan. Department of Internal Medicine Seoul National University HospitalSeoul 110-744South Korea. Department of Gastrointestinal Oncology The First People's Hospital of FoshanFoshanGuangdong 528000P.R.China. Department of Inter-nal Medicine Yonsei University College of MedicineSeoul 120-752South Korea. Department of Medical Oncology The Sixth Ailiated HospitalSun Yat-sen UniversityGuangzhouGuangdong 510655P.R.China. Depart-ment of Hematology-Oncology Chonnam National University Medical SchoolGwangju 519-809South Korea. Department of Digestive Oncology Tianjin Medical University Cancer Institute and HospitalTianjin 300060P.R.China. Department of Internal Medicine Seoul National University Bundang Hos-pitalSeoul National University College of MedicineSeongnam 463-707South Korea. Department of Medical Oncology Union Hospital of Tongji Medical College

Background: Capecitabine and irinotecan combination therapy(XELIRI) has been examined at various dose levels to treat metastatic colorectal cancer(m CRC). Recently, in the Association of Medical Oncology of the German Cancer Society(AIO) 0604 trial, tri?weekly XELIRI plus bevacizumab, with reduced doses of irinotecan(200 mg/m^2 on day 1) and capecitabine(1600 mg/m^2 on days 1–14), repeated every 3 weeks, has shown favorable tolerability and eicacy which were comparable to those of capecitabine and oxaliplatin(XELOX) plus bevacizumab. The doses of capecit?abine and irinotecan in the AIO trial are considered optimal. In a phase I/II study, XELIRI plus bevacizumab(BIX) as second?line chemotherapy was well tolerated and had promising eicacy in Japanese ***: The Asian XELIRI Projec T(AXEPT) is an East Asian collaborative, open?labelled, randomized, phase Ⅲ clinical trial which was designed to demonstrate the non?inferiority of XELIRI with or without bevacizumab versus standard FOLFIRI(5?fluorouracil, leucovorin, and irinotecan combination) with or without bevacizumab as second?line chemo?therapy for patients with m CRC. Patients with 20 years of age or older, histologically conirmed m CRC, Eastern Coop?erative Oncology Group performance status 0–2, adequate organ function, and disease progression or intolerance of the irst?line regimen will be eligible. Patients will be randomized(1:1) to receive standard FOLFIRI with or with?out bevacizumab(5 mg/kg on day 1), repeated every 2 weeks(FOLIRI arm) or XELIRI with or without bevacizumab(7.5 mg/kg on day 1), repeated every 3 weeks(XELIRI arm). A total of 464 events were estimated as necessary to show non?inferiority with a power of 80% at a one?sided α of 0.025, requiring a target sample size of 600 patients. The 95% conidence interval(CI) upper limit of the hazard ratio was pre?speciied as less than ***: The Asian XELIRI Projec T is a multinational phase III trial being conducted to provide evidence fo

关键词： Metastatic colorectal cancer Randomized phase Ⅲ clinical trial XELIRI Bevacizumab Second-line therapy

Is there diversity among UGT1A1 polymorphism in Japan?

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastrointestinal Oncology 2012年第7期4卷 170-175页

作者： Michiya Kobayashi Shoichi Hazama Kenichi Takahashi Koji Oba Naoko Okayama Mitsuaki Nishioka Yuji Hinoda Masaaki Oka Ken Okamoto Hiromichi Maeda Daisuke Nakamura junichi sakamoto Hideyuki Mishima Department of Human Health and Medical Sciences Kochi Medical School Nankoku 783-8505 Japan Department of Digestive Surgery and Surgical Oncology (Surgery Ⅱ) Yamaguchi University Graduate School of Medicine Ube Yamaguchi 755-8505 Japan Department of Surgery Aomori Prefectural Central Hospital Aomori 030-8553 Japan Translational Research and Clinical Trial Center Hok-kaido University Hospital Sapporo 060-8638 Japan Division of Laboratory Yamaguchi University Hospital Ube Yamaguchi 755-8505 Japan Department of Oncology and Laboratory Medicine Yamaguchi University Graduate School of Medicine Ube Yama-guchi 755-8505 Japan Tokai University School of Medicine Is-ehara Kanagawa 259-1131 Japan Young Leaders Program in Healthcare Administration Nagoya University Graduate School of Medicine Nagoya 466-8550 Japan Department of Surgery Osaka National Hos-pital Osaka 565-0871 Japan

AIM: To investigate into the diversity of UGT1A1 polymorphism across three different districts in Japan and highlight genetic differences among the population in Japan. METHODS: We enrolled 50 healthy volunteers from each of the Yamaguchi (western part of Japan), Kochi(southern part of Japan) and Akita (northern part of Japan) prefectures. Blood samples (7 mL) were collected from each participant and stored in EDTA for subsequent genotyping by fragment size analysis, direct sequencing and TaqMan assay of UGT1A1*28, UGT1A7*3/UGT1A9*22 and UGT1A1*93/UGT1A1*6/ UGT1A1*27/UGT1A1*60/UGT1A7 (-57), respectively. RESULTS: The only statistically significant differences in allele polymorphisms among the group examined were for UGT1A1*6. The Akita population showed more UGT1A1*6 heterozygosity (P = 0.0496). CONCLUSION: Our study revealed no regional diversity among UGT1A1, UGT1A7 or UGT1A9 polymorphisms in Japan.

关键词： UGT1A1 gene Polymorphism Diversity

Selection of treatment modality for hepatocellular carcinoma according to the modified Japan Integrated Staging score

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2008年第1期14卷 58-63页

作者： Atsushi Nanashima junichi Masuda Satoshi Miuma Yorihisa Sumida Takashi Nonaka Kenji Tanaka Shigekazu Hidaka Terumitsu Sawai Takeshi Nagayasu Division of Surgical Oncology Department of Translational Medical Sciences Nagasaki University Graduate School of Biomedical Sciences 1-7-1 Sakamoto Nagasaki 852-8501 Japan Second Department of Internal Medicine Department of Translational Medical Sciences Nagasaki University Graduate School of Biomedical Sciences 1-7-1 Sakamoto Nagasaki 852-8501 Japan First Department of Internal Medicine Department of Translational Medical Sciences Nagasaki University Graduate School of Biomedical Sciences 1-7-1 Sakamoto Nagasaki 852-8501 Japan

AIM： To compare the prognosis of patients who underwent hepatectomy and ablation using the modified Japan Integrated Staging score （mJIS）. METHODS： We examined the clinicopathologic records and patient outcomes in 278 HCC patients including 226 undergoing hepatectomy and 52 undergoing ablation therapy. RESULTS： Cirrhosis was more frequent in the ablation group. Tumor size, number and presence of vascular invasion were significantly higher in the operation group compared to the ablation group. The local recurrence rate adjacent to treated lesions was significantly higher in the ablation group compared to the operation group （P 〈 0.05）. The 3- and 5-year survival rates in the ablation and the operation group were 66% and 78%, and 50% and 63%, respectively, but not significantly different. Over 50% survival rates were observed in patients with a *** score of 0-2 in both groups. However, survival rates with a score of 3-5 in both groups were significantly lower. CONCLUSION： According to the mJIS system, both local treatments could be selected for patients with a score of 0-2. However, for patients with a score more than 3, liver transplantation might be a better option in patients with HCC.

关键词： Hepatocellular carcinoma Hepatectomy,Ablation Modified Japan integrated staging score Liver transplantation

经皮冠状动脉成形术中的冠状动脉破裂原因分析

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中国临床医学 2010年第4期17卷 480-483页

作者：邱朝晖 Kataoka Toru 郭新贵 Kobayashi Yoshiki Nishioka Hiroki 张煜 sakamoto Kazuo Yoshi mura Takayoshi Shi mada Kenei Yoshikawa junichi 复旦大学附属华东医院心内科上海200040 日本大阪市立大学附属医院循环器内科日本大阪5450051 日本大阪市泉尾医院内科日本大阪5500024 日本大阪市育和会纪念医院心内科日本大阪5440004 日本大阪掖济会医院心内科日本大阪5500022

目的：探讨冠状动脉成形术中冠状动脉破裂的可能原因。方法：对所有介入治疗前的靶病变行定性和定量造影分析,并选择在发生冠状动脉破裂前最近一次的血管内超声（IVUS）图像进行分析。结果：在5个心脏介入中心总共1 506例经皮冠状动脉... 详细信息

目的：探讨冠状动脉成形术中冠状动脉破裂的可能原因。方法：对所有介入治疗前的靶病变行定性和定量造影分析,并选择在发生冠状动脉破裂前最近一次的血管内超声（IVUS）图像进行分析。结果：在5个心脏介入中心总共1 506例经皮冠状动脉成形术（PCI）患者中,发生冠状动脉破裂15例（1.0%）,其中6例与操作导丝相关,1例与单纯球囊扩张相关,8例与支架植入相关。6例与导丝相关的破裂均由亲水涂层或中等硬度导丝所致,靶病变包括3例闭塞、4例偏心和3例分叉病变。与球囊或支架相关冠状动脉破裂包括6例偏心、6例中等至严重钙化病变。有血管内超声分析的5例,其病变偏心率均小于0.4,钙化弓在42~109度。除了单纯球囊破裂病例,在所有支架植入导致的破裂,球囊/管腔比值均超过1.3。所有与导丝相关冠状动脉破裂属于EllisⅡ级,与球囊或支架相关的2例属Ⅱ级,7例属Ⅲ级。结论：导丝相关的冠状动脉破裂常发生在采用亲水涂层或中等硬度导丝对偏心、分叉或闭塞病变进行操作;球囊或支架相关冠状动脉破裂经常与球囊尺寸过大或压力过大有关,常发生在偏心和伴钙化的病变处。

关键词：经皮冠状动脉成形术冠状动脉破裂冠状动脉造影定量分析血管内超声